CALC
CalciMedicaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The remaining long thesis is that KOURAGE's stoppage does not kill the platform: management says its review found no drug-related toxicity, AP remains active with a possible pivotal path in 1H 2026, and even modest regulatory progress could re-rate a sub-$100 million market cap sharply [#PR-2026-01-28][#PR-2026-03-03].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Acute pancreatitis pivotal-program design may slip or fail to produce a commercially credible regulatory path.
Momentum
99
Value
41
Sentiment
22
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.45 · Bull $1.40 · Bear $0.12
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $14.25
Why
Momentum99 · Δ7d -
Value41 · Δ7d +0.1
Sentiment22 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
99
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
22
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 99.0 / Value 41.1 / Sentiment 21.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$13.3M
Beta
0.49
Shares Out
14.4M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.62
Rev YoY
-
EPS YoY
-2.6%
Gross Margin
-
Op Margin
-
Net Debt
-$18.67M
Current Ratio
4.04
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology